These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17890890)

  • 21. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
    Cleary JM; Tanabe KT; Lauwers GY; Zhu AX
    Oncologist; 2009 Nov; 14(11):1095-105. PubMed ID: 19880627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New therapy options in colorectal carcinoma].
    Folprecht G; Köhne CH
    Ther Umsch; 2004 Jun; 61(6):373-8. PubMed ID: 15253162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete resection of unresectable liver metastases from colorectal cancer without deterioration of liver function after cetuximab and irinotecan: two case reports.
    Karasaki T; Sano K; Takamoto T; Kinoshita H; Tateishi R; Takemura T; Makuuchi M
    Hepatogastroenterology; 2010; 57(104):1526-8. PubMed ID: 21443115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases.
    Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1205-8. PubMed ID: 21772113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
    Larsen FO; Boisen MK; Fromm AL; Jensen BV
    Acta Oncol; 2012 Feb; 51(2):231-3. PubMed ID: 21936753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Novel molecular approaches in the therapy of advanced colorectal carcinoma].
    Vanhoefer U
    Onkologie; 2003 Dec; 26 Suppl 7():70-4. PubMed ID: 14716146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
    Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
    J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
    Carneiro BA; Ramanathan RK; Fakih MG; Krishnamurthi SS; Lembersky BC; Stoller RG; Lancaster SL; Pinkerton RA; Crandall TL; Schmotzer AR; Potter DM; Bahary N
    Clin Colorectal Cancer; 2012 Mar; 11(1):53-9. PubMed ID: 21813336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
    Gotlib V; Khaled S; Lapko I; Mar N; Saif MW
    Anticancer Drugs; 2006 Nov; 17(10):1227-9. PubMed ID: 17075324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
    Huang CW; Yeh YS; Ma CJ; Tsai HL; Chen CW; Huang MY; Lu CY; Wu JY; Wang JY
    Chemotherapy; 2017; 62(1):80-84. PubMed ID: 27654129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic colorectal cancer: current systemic treatment options.
    Board RE; Valle JW
    Drugs; 2007; 67(13):1851-67. PubMed ID: 17722954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.
    Vincenzi B; Santini D; Russo A; Spoto C; Venditti O; Gasparro S; Rizzo S; Zobel BB; Caricato M; Valeri S; Coppola R; Tonini G
    Cancer; 2009 Oct; 115(20):4849-56. PubMed ID: 19626652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study.
    Feliu Batlle J; Cuadrado E; Castro J; Caldés T; Belda C; Sastre J; Barriuso J; Martínez Marín V; Díaz-Rubio E; González-Barón M
    Chemotherapy; 2011; 57(2):138-44. PubMed ID: 21447947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of attachment to or invasion of major intrahepatic vessels by colorectal liver metastases according to prehepatectomy chemotherapy regimen.
    Tanaka K; Nakagawa K; Yabushita Y; Hiroshima Y; Matsuo K; Ota M; Ichikawa Y; Taguri M; Tanabe M; Koda K; Endo I
    Surgery; 2014 May; 155(5):936-44. PubMed ID: 24656858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
    Halama N; Herrmann C; Jaeger D; Herrmann T
    Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncological management of unresectable liver metastases.
    Prenen H; Van Cutsem E
    Dig Dis; 2012; 30 Suppl 2():137-42. PubMed ID: 23207946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.